Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for IN8bio, Inc. (INAB : NSDQ)

• Company Description    IN8bio Inc. is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company's principal candidate includes INB-200, which are in clinical stage. IN8bio Inc. is based in New York. Number of Employees: 19

• Price / Volume Information    Yesterday's Closing Price: $2.58 Daily Weekly Monthly 20 Day Moving Average: 20,350 shares Shares Outstanding: 18.84 (millions) Market Capitalization: $48.60 (millions) Beta: 52 Week High: $10.32 52 Week Low: $2.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -24.34% -14.78% 12 Week -41.76% -35.97% Year To Date -41.23% -28.19%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 350 5th Avenue Suite 5330 - New York,NY 10118 USA ph: 646-600-6438 fax: - dbuck@soleburytrout.com http://www.in8bio.com

• General Corporate Information    Officers William Ho - Chief Executive Officer and Director Alan S. Roemer - Chairman Patrick McCall - Chief Financial Officer and Secretary Peter Brandt - Director Emily Fairbairn - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45674E109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 09/09/22 Share - Related Items Shares Outstanding: 18.84 Most Recent Split Date: (:1) Beta: Market Capitalization: $48.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.38 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.48 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -57.14% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -82.53 12/31/21 - - 09/30/21 - - ROA 03/31/22 - -53.40 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - 16.09 12/31/21 - 17.28 09/30/21 - 20.31 Quick Ratio 03/31/22 - - 12/31/21 - 17.28 09/30/21 - 20.31 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 1.74 12/31/21 - 2.04 09/30/21 - 2.29 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.01 12/31/21 - 0.01 09/30/21 - 0.01 Debt-to-Capital 03/31/22 - 0.61 12/31/21 - 0.70 09/30/21 - 0.79

Powered by Zacks Investment Research ©